Bristol-Myers Squibb Completes Amylin Purchase

Bristol-Myers Squibb (B-MS) yesterday announced that they have completed their $5 billion purchase of Amylin and its diabetes franchise, meaning they can now progress onto a planned marketing alliance with drug giant AstraZeneca. The New York-based drug maker, who agreed to buy Amylin on the 1st July, confirmed that they have now successfully finalised their

Continue Reading

US Judge Backs AstraZeneca’s Seroquel XR patent

AstraZeneca announced earlier today that a US district court has ruled that the formulation patent for its extended-release version of the antipsychotic blockbuster, Seroquel XR, is valid and has been infringed by generics companies. The court in New Jersey found the formulation patent protecting Seroquel XR (quetiapine fumarate) extended-release tablets to be valid and ruled

Continue Reading

AstraZeneca Appoints Johansson as Chairman

AstraZeneca announced yesterday that they have appointed Swedish executive Leif Johansson from telecoms group Ericsson as chairman. Leif Johansson will be proposed to shareholders for election as a Non-Executive Director at the Company’s Annual General Meeting on 26 April 2012, with the aim that he will take over completely from Louis Schweitzer on the 1

Continue Reading

Europe Approves AstraZeneca’s Caprelsa for Medullary Thyroid Cancer

AstraZeneca announced earlier today that the European Commission has granted marketing authorisation for their thyroid cancer pill, Caprelsa (vandetanib). The approval was given for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.  The announcement comes three months after the European Medicines Agency’s Committee for

Continue Reading

Enlight Forms Two New Partnerships

Enlight Biosciences LLC announced yesterday that they have formed new partnerships with AstraZeneca and Novo Nordisk.  As partners, AstraZeneca and Novo Nordisk will have the chance to collaborate and invest in the development of potentially transformational technologies with application to their therapeutic programs. Enlight is a unique entrepreneurial partnership with major pharmaceutical companies and leading

Continue Reading

EU Approval for Komboglyze and Onglyza

AstraZeneca and Bristol-Myers Squibb are celebrating after European regulators approved two of their diabetes drugs. AstraZeneca and Bristol-Myers Squibb Company announced today that the European Commission has granted marketing authorisation for Komboglyze,  which combines the DPP-4 inhibitor Onglyza (saxagliptin) with metformin in a once-a-day tablet. The combination is to be used as an adjunct to

Continue Reading

NICE Reject Breast Cancer Drug Faslodex

England and Wales’ cost watchdog, NICE, yesterday reiterated their assessment that AstraZeneca’s breast cancer drug Faslodex does not represent good use of NHS funds and has not been proven to be better than current treatments. The National Institute for Health and Clinical Excellence (NICE) has published their  final appraisal determination, saying that they do not

Continue Reading

NICE Issues Final Draft OK For Brilique

The UK National Institute for Health and Clinical Excellence (NICE) has issued a final draft guidance recommending the use of AstraZeneca’s antiplatelet drug Brilique (ticagrelor) in the treatment of acute coronary syndromes (ACS). Every year, around 200,000 people in England are diagnosed with acute coronary syndromes, which cover a range of conditions from unstable angina

Continue Reading